Search

everythinglearnresearchcommunity

for

Search:↓

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Tofacitinib taken by mouth helps treat hair loss in children.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.